These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18338430)

  • 41. Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report.
    Jülg B; Bogner JR; Goebel FD
    AIDS; 2006 Jul; 20(11):1563. PubMed ID: 16847416
    [No Abstract]   [Full Text] [Related]  

  • 42. Tipranavir: a review of its use in the management of HIV infection.
    Orman JS; Perry CM
    Drugs; 2008; 68(10):1435-63. PubMed ID: 18578560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
    Huff B
    GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
    [No Abstract]   [Full Text] [Related]  

  • 44. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
    Temesgen Z; Feinberg J
    Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tipranavir gets approved.
    AIDS Patient Care STDS; 2005 Sep; 19(9):615-6. PubMed ID: 16245408
    [No Abstract]   [Full Text] [Related]  

  • 46. Freedom of choice.
    Vazquez E
    Posit Aware; 1996; 7(3):9, 19. PubMed ID: 11363432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA notifications. Potential serious effect of combination saquinavir-ritonavir.
    AIDS Alert; 2010 Apr; 25(4):45-6. PubMed ID: 20564774
    [No Abstract]   [Full Text] [Related]  

  • 48. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
    AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
    [No Abstract]   [Full Text] [Related]  

  • 49. Relative antiviral efficacy should not be inferred from cross-trial comparisons.
    Hall D
    HIV Med; 2007 Nov; 8(8):570-1; author reply 571-2. PubMed ID: 17944692
    [No Abstract]   [Full Text] [Related]  

  • 50. FDA approves 2 new protease inhibitors: ritonavir (Norvir) and Crixivan (Indinavir sulfate). Food and Drug Administration.
    Schouten JT
    STEP Perspect; 1996; 8(1):7-8. PubMed ID: 11363592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
    Gathe JC; Pierone G; Piliero P; Arasteh K; Rubio R; Lalonde RG; Cooper D; Lazzarin A; Kohlbrenner VM; Dohnanyi C; Sabo J; Mayers D
    AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atazanavir in children.
    Prescrire Int; 2011; 20(118):177. PubMed ID: 21751749
    [No Abstract]   [Full Text] [Related]  

  • 54. Tipranavir: a protease inhibitor for HIV salvage therapy.
    Dong BJ; Cocohoba JM
    Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protease inhibitors: the current status.
    Dauer B
    J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
    [No Abstract]   [Full Text] [Related]  

  • 56. PI monotherapy effective as maintenance.
    AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
    [No Abstract]   [Full Text] [Related]  

  • 57. [Tipranavir (used with ritonavir)].
    Taéron C
    Rev Infirm; 2006 Jan; (117):39-40. PubMed ID: 16502825
    [No Abstract]   [Full Text] [Related]  

  • 58. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
    Lascar M; Cartledge JD
    J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
    [No Abstract]   [Full Text] [Related]  

  • 59. 96-week data from CASTLE study presented.
    Proj Inf Perspect; 2008 Dec; (47):3-4. PubMed ID: 19230058
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
    Walmsley SL; Cotte L; Rusconi S; Ward DJ; Hicks CB; Meier U; Valdez H; Boucher CA
    AIDS; 2007 Oct; 21(16):2245-8. PubMed ID: 18090054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.